CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-24). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1882 · Search date 2026-07-24 · Methodology v0.6

Ondansetron,
does it really help with Prevention of nausea and vomiting during the first 24 hours after surgery?

30-Second Summary
B
Evidence Grade B · 77 · Safety caution
Ondansetron reliably lowers nausea and vomiting during the first day after surgery
Headache and constipation can occur. QT prolongation and rare arrhythmia warrant caution with congenital long QT, electrolyte abnormalities, or other QT-prolonging medicines.
What the
research shows
Ondansetron earns B with 77 points because it repeatedly reduces postoperative nausea and vomiting. IMPACT randomized 5,199 patients and analyzed 5,161 for the 24-hour primary outcome, finding 28.5% versus 38.5% and a 26% relative-risk reduction, P<0.001.
What the
ads claim
One dose does not completely prevent symptoms in everyone. Absolute benefit depends on baseline risk and the accompanying prevention strategy.
*

Useful facts when choosing a product

  • IMPACT randomized 5,199 patients and analyzed 5,161 for ondansetron.
  • Ondansetron 4 mg intravenously was given during the final 20 minutes of surgery.
  • The primary outcome was any nausea, retching, or vomiting within 24 hours.
Gap Measurement · Verdict 1882 · B 77
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

IMPACT factorially randomized 5,199 high-risk surgical patients, and 5,161 entered the actual ondansetron primary analysis. Postoperative nausea or vomiting occurred in 735 of 2,576 versus 996 of 2,585, a 26.0% relative reduction (95% CI 19.9% to 31.5%), P<0.001. Weibel 2020 synthesized 282 randomized trials and 50,812 participants and estimated RR 0.55 for postoperative vomiting.

02

Why this is classified as B (77)

A successful large blinded trial and extensive randomized replication support B with 77 points.

Counterpoint. QT prolongation risk and interacting medicines require individual review.

Rejudgment record. Cross-check applied — Successful patient-centered primary outcome in a large blinded factorial trial with replication across 282 randomized trials

Scoring profile behind this grade
EndpointPPatient-reported treatment goal - the symptom is the goal
ReplicationR2Independently replicated across trials
IndependenceI1Mixed funding sources
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (B).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Prevention of postoperative nausea or vomiting within 24 hoursBThe IMPACT primary outcome succeeded.
Prevention of postoperative vomitingBThe network RR was 0.55.
Added effect within multimodal prophylaxis for high-risk patientsBThe factorial trial found largely independent intervention effects.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Apfel CC et al. 2004 (IMPACT)Twenty-eight-center factorial randomized trial with blinded outcome assessment1Joint support from universities, NIH, foundations, public funding, AstraZeneca, and GSKPrimary outcome of nausea or vomiting within 24 hours28.5% versus 38.5%, 26.0% relative reduction, P<0.001; successfulLarge direct confirmatory trial
Weibel S et al. 2020Cochrane network meta-analysis50,812Public and nonprofit Cochrane support; mixed funding among included trialsPostoperative vomiting and serious adverse eventsOndansetron vomiting RR 0.55 (95% CI 0.51 to 0.60)Extensive replication
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-24).

Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004;350(24):2441-2451. PMID: 15190136. DOI: 10.1056/NEJMoa032196.
checked
Weibel S, Rücker G, Eberhart LHJ, et al. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis. Cochrane Database Syst Rev. 2020;2020(10):CD012859. PMID: 33075160. DOI: 10.1002/14651858.CD012859.pub2.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none

Cite this verdict

Ondansetron x prevention of postoperative nausea and vomiting Evidence Grade B card
[Chamgap] Ondansetron x prevention of postoperative nausea and vomiting — Evidence Grade B·77. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/ondansetron-postoperative-nausea-vomiting-prevention/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.